TCRX TCRX
Company Profile ↓Company Overview
TCRX (TCRX) is a publicly traded company listed on with a market capitalization of $44.38M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 75.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $10.32M (+266.7% YoY); net profit $-129.77M.
- Trailing 12 Months Year-on-year growth — revenue +266.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 75.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 75.64% |
| 1 Year: | 266.65% |
Stock Price Performance
| 1 Year: | -51.85% |
| 6 Months: | -21.69% |
| 3 Months: | -35.54% |
| 1 Month: | -27.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 75.6% over 5 years.
CONS
- Trading 69.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 290.00K | 2.03M | 2.85M | 2.41M | 3.02M | 4.06M | 3.36M | 6.80M | 3.15M | 3.89M | 566.00K | 536.00K | 1.05M | - | 2.17M | 3.08M | 2.51M | 2.57M | 982.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.42M | 41.73M | 39.56M | 26.43M | 30.12M |
| Operating Income | -5.62M | -7.17M | -7.92M | -10.68M | -15.84M | -16.16M | -15.25M | -16.58M | -22.74M | -24.61M | -24.75M | -31.37M | -34.11M | -32.62M | - | -36.25M | -38.65M | -37.05M | -23.86M | -29.14M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.77M | -35.56M | -34.24M | -21.55M | -27.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 679.00K | 689.00K | 699.00K | 702.00K | 689.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.61M | -7.17M | -7.91M | -10.67M | -15.84M | -16.16M | -15.10M | -16.25M | -22.56M | -24.05M | -23.00M | -30.14M | -31.66M | -29.89M | - | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M |
| Diluted EPS | - | - | - | -7.69 | -0.80 | -0.67 | -0.63 | -0.67 | -0.93 | -0.51 | -0.24 | -0.32 | -0.28 | -0.25 | - | -0.26 | -0.28 | -0.28 | -0.18 | -0.22 |
| R&D Expense | 4.50M | 5.81M | 7.34M | 10.80M | 14.21M | 14.69M | 14.49M | 15.03M | 21.78M | 21.23M | 22.74M | 24.86M | 26.88M | 26.26M | - | 29.79M | 32.63M | 31.69M | - | 21.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.08M | - | 13.54M | 21.05M | 2.82M | 10.32M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 80.17M | 114.51M | 137.64M | 146.14M |
| Operating Income | -26.23M | - | -66.64M | -93.46M | -134.82M | -135.81M |
| EBITDA | - | - | -59.91M | -80.10M | -119.74M | -124.13M |
| Interest Expense | - | - | 1.18M | 3.76M | 3.65M | 2.77M |
| Pretax Income | - | - | -66.22M | -89.22M | -127.50M | -129.77M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -26.13M | - | -66.22M | -89.22M | -127.50M | -129.77M |
| Diluted EPS | - | - | -2.75 | -1.36 | -1.14 | -1.00 |
| R&D Expense | 20.58M | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 49.74M | - | 199.09M | 272.15M | 371.12M | 228.79M |
| Current Assets | - | - | - | 124.13M | 194.24M | 292.72M | 157.21M |
| Cash & Equivalents | - | 34.79M | - | 120.03M | 133.36M | 178.69M | 152.41M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 32.52M | - | 99.66M | 121.28M | 130.15M | 105.67M |
| Current Liabilities | - | 17.45M | - | 17.30M | 29.82M | 35.96M | 18.70M |
| Long Term Debt | - | - | - | 29.29M | 26.70M | 32.07M | 32.53M |
| Total Debt | - | - | - | 85.98M | 92.43M | 97.38M | 94.14M |
| Total Equity | -17.14M | -42.46M | - | 99.43M | 150.87M | 240.97M | 123.12M |
| Shares Outstanding | - | - | - | 24.23M | 47.83M | 56.59M | 56.90M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.02M | - | -66.50M | -61.36M | -110.82M | -135.32M |
| Investing Cash Flow | -4.24M | - | -4.22M | -60.76M | -52.61M | 109.37M |
| Financing Cash Flow | 288.00K | - | 29.36M | 135.44M | 208.76M | -336.00K |
| Capital Expenditure | -4.24M | - | -4.22M | -3.15M | -3.83M | -4.41M |
| Free Cash Flow | -7.26M | - | -70.73M | -64.50M | -114.65M | -139.73M |
| Net Change in Cash | - | - | -41.37M | 13.33M | 45.33M | -26.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -2,417.8% | - | -492.3% | -444.0% | -4,787.7% | -1,315.4% |
| Net Margin % | -2,408.0% | - | -489.3% | -423.9% | -4,527.7% | -1,256.8% |
| ROE % | 61.5% | - | -66.6% | -59.1% | -52.9% | -105.4% |
| ROCE % | -81.2% | - | -36.7% | -38.6% | -40.2% | -64.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOVEFka0NhbzlXdC1DdlpxZVhGMW5xTnk2LXRyNG94cHZUOWJJRks4OUFSZVdkRE5yWkI0dS1SOExFbjhNQkdTTldieTJ5MnBjMDdJN0xUTG5vdU10MGdNVkF4aXFQdkstVmFmMnBVTV9Xbm9XbllCNXNydjR4QlBfdDJTVjAtNnFmSnFINk…
TScan’s Phase 3 Cancer Trial Enrolls Across U.S.; Data Expected 2028 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQNFAwSkRwai1WdjVlQkVrbWljQUE4YTlzUnZDN2hjenJXOVo1MC1kSUlPWFFhOGFTNm1VMzZNQll3S2VqS3M5VmE2N2s3T0JLdGdhNnE0MFRGWGc1REMzNkRXRmxIM2pQV2l4b1VaYTJGWnFjMC1jbHVsQTlKT2lpTW5abzFlS2o4SmpnYV…
TCRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9yTmkwUGFCYzlqanRXemx3QkJ1dkRWLS0wZHNvOWtyb0RUYUh1VFNmSF8xa0tTeWFjc2djWVUzajdJV3FQd1E?oc=5" target="_blank">TCRX</a> <font color="#6f6f6f">Finviz</font>…
Tilray Brands (TLRY) Stock Forecast & Analyst Ratings - Moomoo
<a href="https://news.google.com/rss/articles/CBMipAJBVV95cUxPMHdaUkp6NnkwMmtveVdmaDV0WUJoUUxsZ0FWRG5xZkl6QzhVTlRpLXNmZ21vLXhYVzJoWnMwMUJMWGlFa2Z2M012eDdrZkJHWnpKcVF5WHE3SDMwQ3RFWjg0RTdTdWx0NXR5ZU93cnJtNkpscGVMWTBEbG8wSEh6Y2ZZNURwOXlfeFZkWn…
TCRX|TScan Therapeutics Inc|Price:0.743|Chg%:-0.031 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1qRVJpUmUwRERwRWt0c2MzbDJwcm5GUmxwX05zbWVqN2IwNF9RTmtrN3dNbjBoaTU3alhnMkhMenBUWllLaEhNQUhra2RpT0ZmX3k1WmwtU0l4a1V5UGUtc1h0ejJ0QXU2eko0QzFR?oc=5" target="_blank">TCRX|TScan Therapeu…
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxObkxkdDZ3blhoZmVXYi1VdXJuQUJhN3hNSENQT08wbFQxZmMyUTlFUGFRUlVlS19wYUxISm56Z3R1cThhXzlsUVhsZGxMQU9KM3FGX0VoaTJoUHotc0paUF9DUTk1dG9RU3RoRF8yeWJFMmdhc3lSYVZoRDg1UGZ3UUY5MS1zWXZJOXh2Qz…
TCRX — Frequently Asked Questions
What is the current share price of TCRX?
As of 2026-08-05 17:25 PDT, TCRX trades at $0.78 on NASDAQ/NYSE. Its 52-week range is $0.72 to $2.52.
What is the market capitalisation of TCRX?
TCRX has a market capitalisation of $44.38M on NASDAQ/NYSE.
What is the P/E ratio of TCRX?
TCRX trades at a trailing price-to-earnings (P/E) ratio of -0.78. Its price-to-book (P/B) ratio is 0.36.
What is the return on equity (ROE) of TCRX?
TCRX has a return on equity (ROE) of -105.40%. Its return on capital employed (ROCE) is -64.64%.
Is TCRX a good stock to buy?
This page provides a data-driven analysis of TCRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.